Medpace Holdings, Inc. revenue
Medpace Holdings, Inc.'s revenue was $2.53bn in fiscal 2025, up 20.0% on the year before. Since fiscal 2015 ($359m) it has grown at a compound 21.6% a year. Over the last twelve months it was $2.84bn.
Revenue history
| Fiscal year | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 359 | 422 | 436 | 705 | 861 | 926 | 1,142 | 1,460 | 1,886 | 2,109 | 2,530 | 2,838 |
| Growth on the year before | — | +17.4% | +3.5% | +61.5% | +22.2% | +7.5% | +23.4% | +27.8% | +29.2% | +11.8% | +20.0% | — |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Oncology | $748M | 29.5% | ▲ 14.8% |
| Metabolic | $745M | 29.4% | ▲ 62.8% |
| Other | $409M | 16.1% | ▼ 5.3% |
| Central Nervous System | $255M | 10.1% | ▲ 40.0% |
| Cardiology | $239M | 9.5% | ▲ 3.9% |
| Antiviral and Anti Infective | $135M | 5.3% | ▼ 13.8% |
From Medpace Holdings, Inc.'s 10-K filed February 10, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Medpace Holdings, Inc. | $2.84bn | 20.4% | 16.8% |
| Fortrea Holdings Inc. | $2.67bn | -3.4% | 0.4% |
| Bio-rad Laboratories, Inc. | $2.59bn | 1.4% | -2.2% |
| Bruker Corp | $3.50bn | 1.6% | 8.8% |
| Qiagen N.V. | $2.09bn | 5.7% | 17.1% |
| Charles River Laboratories | $4.00bn | -0.7% | -1.5% |
Compare with peers
- Fortrea Holdings Inc. revenue
- Bio-rad Laboratories, Inc. revenue
- Bruker Corp revenue
- Qiagen N.V. revenue
- Charles River Laboratories revenue
Head to head: FTRE vs MEDPBIO vs MEDPBRKR vs MEDPMEDP vs QGEN
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies